Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Payables: 2021-2025

Historic Payables for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $1.1 million.

  • InMed Pharmaceuticals' Payables rose 11.72% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 3.48%. This contributed to the annual value of $1.4 million for FY2025, which is 15.10% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Payables of $1.1 million as of Q3 2025, which was down 19.52% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Payables peaked at $3.4 million during Q4 2021, and registered a low of $1.0 million during Q3 2024.
  • Moreover, its 3-year median value for Payables was $1.4 million (2024), whereas its average is $1.4 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Payables increased by 23.14% in 2022 and then crashed by 55.71% in 2023.
  • InMed Pharmaceuticals' Payables (Quarterly) stood at $3.4 million in 2021, then plummeted by 42.34% to $2.0 million in 2022, then crashed by 34.65% to $1.3 million in 2023, then increased by 6.49% to $1.4 million in 2024, then rose by 11.72% to $1.1 million in 2025.
  • Its Payables stands at $1.1 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.